Business Context and Reporting Period
This Form 8-K Current Report was filed by ENDRA Life Sciences Inc. on April 21, 2022. The filing serves as a Regulation FD disclosure regarding a significant capital raise event.
Key Financial Metrics
The filing details a specific equity financing transaction rather than providing comprehensive period-end financial statements (e.g., revenue, net income, or total debt).
- Gross Proceeds Raised: $8.7 million (year-to-date).
- Shares Sold: Approximately 20.6 million shares of common stock.
- Average Sale Price: $0.42 per share.
- Facility Used: At-The-Market (ATM) Issuance Sales Agreement with Ascendiant Capital Markets LLC (dated June 21, 2021).
Note: The filing text does not provide clear values for revenue, profit, operating cash flow, margins, total debt, or liquidity ratios.
Material Changes
The primary material change reported is the increase in cash resources and the expansion of the company's share count resulting from the ATM sales. The company has successfully utilized its equity facility to raise capital in the current fiscal year.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, forward-looking outlook statements, or specific risk factors beyond standard legal disclaimers. The document includes a standard "No Offer or Solicitation" statement, clarifying that the communication does not constitute an offer to sell securities in jurisdictions where such an offer would be unlawful.
Investor Verification Checklist
- Verify the total number of shares outstanding post-transaction to assess dilution impact.
- Review the full text of the press release (Exhibit 99.1) for details on the intended use of the $8.7 million proceeds.
- Check the remaining capacity available under the ATM agreement with Ascendiant Capital Markets LLC.
- Confirm the company's current cash position and runway in the most recent 10-Q or 10-K filing.